Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Suspended × talimogene laherparepvec × Clear all

Phase

Status

Completed 6 Active not recruiting 5 Recruiting 2 Withdrawn 1 Unknown 1 Terminated 1 Suspended 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Specimen Handling 7 Magnetic Resonance Spectroscopy 7 Biopsy 6 pembrolizumab 4 Cisplatin 4 Capecitabine 4 Radiosurgery 3 Nivolumab 3 Irinotecan 3 Fluorouracil 3 Etoposide 3 Docetaxel 3 Cyclophosphamide 3 Bevacizumab 3 trifluridine tipiracil drug combination 2 tazemetostat 2 spartalizumab 2 lenvatinib 2 balstilimab 2 atezolizumab 2 Vincristine 2 Radiation 2 Prednisone 2 Pemetrexed 2 Paclitaxel 2 Oxaliplatin 2 Mitoxantrone 2 Leucovorin 2 Lenalidomide 2 Gemcitabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡